Results 51 to 60 of about 259,058 (180)
Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)
ABSTRACT Background Stereotactic ablative radiotherapy (SABR) is emerging as an alternative treatment for patients with locally recurrent prostate cancer after previous radiation. This approach allows for precise target coverage while limiting toxicity to surrounding organs.
Andre G. Gouveia +12 more
wiley +1 more source
ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento +15 more
wiley +1 more source
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki +6 more
wiley +1 more source
Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
Androgen deprivation therapy is commonly used in combination with radiotherapy as part of the definitive treatment for men with clinically localized and locally advanced prostate cancer.
Matthew E. Johnson, Mark K. Buyyounouski
core +1 more source
Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use
ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and ...
Hamza Abohamra, Keenau Mark Pearce
wiley +1 more source
ABSTRACT Background Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic ...
Cem Onal +4 more
wiley +1 more source
Where does fat regionally accumulate during androgen deprivation therapy?
Where does fat regionally accumulate during androgen deprivation ...
Trish Livingston (13098306) +6 more
core
ABSTRACT Background The prognostic significance of time to metastasis (TTM) following radical prostatectomy in patients with metachronous metastatic hormone‐sensitive prostate cancer (mHSPC) remains uncertain. We performed a secondary analysis of patient‐level data from the phase 3 SWOG 1216 randomized clinical trial to evaluate whether TTM is ...
Nicolas Sayegh +15 more
wiley +1 more source
Complications of androgen deprivation therapy in prostate cancer / a review
Androgen deprivation therapy (ADT) is the standard therapy for advanced prostate cancer. However, it encompasses several adverse effects, with impact on patient’s quality of life and, eventually, on overall survival.
Santos, J.C. +10 more
core
ABSTRACT Background Circulating steroid trajectories after robot‐assisted radical prostatectomy are poorly characterized from the day‐of‐surgery baseline, and relevant biology extends beyond testosterone and dihydrotestosterone to adrenal‐derived 11‐oxygenated androgens and steroid conjugate turnover.
Jiri Heracek +8 more
wiley +1 more source

